(Total Views: 319)
Posted On: 07/02/2019 8:46:04 AM
Post# of 149265
If the results with mTNBC are excellent this is an example of how fast medication can be approved.
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) https://seekingalpha.com/pr/17561357?source=ansh $IOVA
FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer.In addition, the company announced that the innovaTIL-04 study is expected to enroll a total of 75 to 100 patients in order to support a BLA submission.
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) https://seekingalpha.com/pr/17561357?source=ansh $IOVA
FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer.In addition, the company announced that the innovaTIL-04 study is expected to enroll a total of 75 to 100 patients in order to support a BLA submission.
(1)
(0)Scroll down for more posts ▼
